Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Saved in:
| Title: | Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. |
|---|---|
| Authors: | Brahmer JR; Johns Hopkins Kimmel Cancer Center, Baltimore, MD., Lee JS; National University Bundang Hospital, Seongnam, Republic of Korea., Ciuleanu TE; Institutul Oncologic Prof Dr Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania., Bernabe Caro R; Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Urban L; Matrai Gyogyintezet, Mátraháza, Hungary., Audigier-Valette C; Orientation Oncologique, Hôpital Sainte Musse, Toulon, France., Lupinacci L; Hospital Italiano De Buenos Aires, Buenos Aires, Argentina., Sangha R; Cross Cancer Institute, Edmonton, AB, Canada., Pluzanski A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Burgers J; Netherlands Cancer Institute, Amsterdam, the Netherlands., Mahave M; Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Ahmed S; University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester, United Kingdom., Schoenfeld AJ; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY., Paz-Ares LG; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain., Reck M; Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany., Borghaei H; Fox Chase Cancer Center, Philadelphia, PA., O'Byrne KJ; Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia., Gupta RG; Bristol Myers Squibb, Princeton, NJ., Bushong J; Bristol Myers Squibb, Princeton, NJ., Li L; Bristol Myers Squibb, Princeton, NJ., Blum SI; Bristol Myers Squibb, Princeton, NJ., Eccles LJ; Bristol Myers Squibb, Princeton, NJ., Ramalingam SS; Winship Cancer Institute, Emory University, Atlanta, GA. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Feb 20; Vol. 41 (6), pp. 1200-1212. Date of Electronic Publication: 2022 Oct 12. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
